Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. by Aridome, K. et al.
British Joumal ofCancer(1998) 78(4), 472-477
© 1998 Cancer Research Campaign
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Summary Midkine (MK) is a growth factor identified as a product of a retinoic acid-responsive gene. A truncated form of MK mRNA, which
lacks a sequence encoding the N-terminally located domain, was recently found in cancer cells. We investigated the expression of the
truncated MK mRNA in specimens of 47 surgically removed human gastrointestinal organs using polymerase chain reaction. Truncated MK
was not detected in all of the 46 corresponding non-cancerous regions. On the other hand, this short MK mRNA was expressed in the primary
tumours in 12 of 16 gastric cancers, 8 of 13 colorectal carcinomas, five of nine hepatocellular carcinomas, two of two oesophageal carcinomas
and one ampullary duodenal cancer. In addition, truncated MK was detectable in all of the 14 lymph node metastases but in none of three
metastatic sites in the liver, suggesting that truncated MK mRNA could become a good marker of nodal metastases in gastrointestinal tract.
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Abnormalities in expression of growth factors and their signal
transduction systems are often correlated with tumorigenesis.
Midkine (MK), found as a product of a retinoic acid-responsive
gene, is a heparin-binding growth factor (Kadomatsu, 1988;
Tomomura et al, 1990; Muramatsu, 1993). MK is structually unre-
lated to fibroblast growth factor, and has about 50% sequence
identity to pleiotrophin (PTN) (Muramatsu, 1993). MK and PTN
promote neurite outgrowth (Merenmies and Rauvala, 1990;
Muramatsu and Muramatsu, 1991) and enhance plasminogen acti-
vator activity of endothelial cells (Kojima et al, 1995a; Kojima et
al, 1995b). Recent evidence indicates a close correlation between
MK overexpression and tumorigenesis. MK was reported to be
strongly expressed in all cases of Wilms' tumour (Tsusui et al,
1993), and WT1, the product of the Wilms' tumour-suppressor
gene, suppresses human MK promoter activity (Adachi et al,
1996). MK expression is increased compared with adjacent non-
cancerous tissue in more than 80% of gastrointestinal carcinomas
such as hepatocellular, oesophageal, pancreatic, colon and
stomach carcinomas (Aridome et al, 1995). Although the
frequency was not high, PTN expression has also been reported to
be increased in some tumours (Czubyko et al, 1996; Schulte et al,
1996). Overexpression of MK has also been seen in breast and
lung carcinomas (Garver et al, 1994a,b). Furthermore, strong MK
expression correlated with worse prognosis of patients with
neuroblastoma and urinary bladder carcinoma (Nakagawara et al,
1995; O'Brien et al, 1996). Overexpression of MK and PTN in
man appears to contribute to the malignant phenotype of carci-
nomas. Firstly, transfection and expression of MK cDNA or PTN
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cDNA transform NIH3T3 cells and these cells can form tumours
in nude mice (Chauhan et al, 1993; Kadomatsu et al, 1997).
Secondly, MK and PTN have angiogenic activity (Czubayko et al,
1996; Schulte et al, 1996; Choudhuri et al, 1997), and ribozyme-
targeting of PTN results in decreased invasion of melanoma
(Czubayko et al, 1996) and choriocarcinoma (Schulte et al, 1996).
A truncated form of MK mRNA, which encodes MK devoid of
the N-terminally located domain, was found in Wilms' tumour,
pancreatic carcinoma, gastric carcinoma, colon carcinoma and
breast carcinoma but not in adjacent normal tissue (Kaname et al,
1996; Miyashiro et al, 1996, 1997). The truncated MK is essen-
tially composed of functionally important C-terminally located
domain (Muramatsu et al, 1994; Kojima et al, 1995c), and is short-
lived because of the lack of N-terminally located domain, which
protects the C-terminally located domain from protease attack
(Matsuda et al, 1996). This truncated form of MK mRNA may
have diagnostic value. As the number of cases examined to date
was small, we examined 47 specimens of gastrointestinal carci-
nomas and corresponding non-cancerous adjacent tissues for the
expression of truncated MK mRNA. Lymph node metastases and
hepatic metastases were also examined to determine whether there
is any correlation between the expression of the truncated form
MK mRNA and metastasis.
MATERIALS AND METHODS
Surgically resected specimens
Specimens were obtained from 47 patients who had undergone
surgery at Kagoshima University Hospital, Kagoshima University,
from July 1992 to December 1994. They were immediately frozen
and kept at -80°C. The samples were identical to those described
previously (Aridome et al, 1995). The mean age of the patients
was 61.5 years and the male/female ratio was 1.9.
472Truncated midkine 473
Table 1 Truncated and full-size MK expression in gastrointestinal tumours and non-cancerous regions using RT-PCR
Case Truncated MK Full-size MK Other information
N PT LN LiM N PT LN LiMa
Gastric Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Colorectal cancer
17
18
19
20
21
22
23
24
25
26
27
28
29
Hepatocellular carcinoma
30
31
32
33
34
35
36
37
38
Pancreatic cancer
39
40
41
42
43
Oesophageal cancer
44
45
+
+
+
+ + +
+
_+
+ +
_ + +
+ + +
+ + +
Ampullary duodenal cancer
46
Liver metastasis from bile duct cancer
47
+ +,
+
n factoP
n2
+ n2
n2
n2
n2
n2
n2
nO
n2
n2
n2
nO
nO
nO
nl
nO
n factor
nl
nl
n2
nl
nO
nO
nO
nl
nO
n3
nO
nO
nO
FPc
FPC
Liver cirrhosis
Liver cirrhosis
Chronic hepatitis
Chronic hepatitis
Liver cirrhosis
Liver cirrhosis
Normal liver
Normal liver
Normal liver
n factor
nO
+ nO
nl
nl
nO SCTd
n factor
nl
n1
n factor
nl
+
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aN, PT, LN and LiM stand for non-cancerous corresponding adjacent tissue, primary tumour, lymph node metastasis and metastasis in the liver respectively.
bn factor indicates histological lymph node metastasis based on the TNM system. CFP indicates familial polyposis as a complicating disease.
dSCT indicates solid and cystic tumour. eNon-cancerous tissues was removed from normal liver.
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Figure 1 MK expression in primary tumours. Figures indicate case numbers (cf. Table 1). Lanes 1, 2, 8, gastric carcinoma; lanes 18,21,26, colon carcinoma;
lanes 31, 34, hepatocellular carcinoma; lane 40, pancreatic carcinoma; lane 44, oesophageal carcinoma
M 1 2 3 9 18 21 26 30 31 34 38 40 44
MK
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Figure 2 Detection of full-size MK cDNA by RT-PCR in non-cancerous tissues. M indicates size marker and figures indicate case numbers (cf. Table 1). Full-
size MK was detected in all but two cases of liver tissue (cases 30 and 38). No truncated-form MK was detected
RNA preparation and Northern blotting analysis PCR
Total cellular RNA was prepared from samples of about 0.5 g of
frozen tissues by acid guanidium thiocyanate phenol-chloroform
extraction (Chomczynski et al, 1987). Total RNA (20 .tg) was
denatured, electrophoresed through 1% agarose gels and trans-
ferred onto Hybond nylon membranes (Amersham UK). The MK
probe was a 487-bp human cDNA fragment (nucleotides 76-562),
and 2-kb-pair human P-actin cDNA (Clontech) was also used as a
reference probe. The membranes were prehybridized, and then
hybridized with radiolabelled probes. Hybridized membranes were
washed twice with 2 x SSC, 0.1% sodium dodecylsulphate (SDS)
at 56°C for 10 min, twice with 0.2 x SSC, 0.1I% SDS at 56°C for
30 min and exposed to X-ray film.
cDNA synthesis
cDNA from total RNA was synthesized with the Superscript II
preamplification system (Gibco- BRL, MD, USA). Briefly, 3 gg of
total RNA was digested with RNAase-free DNAase, incubated at
70°C to inactivate the enzyme and denatured and hybridized with
random hexamer primers. Then first-strand cDNA was synthe-
sized by reverse transcriptase and RNA was digested by RNAase
H. The first-strand cDNA was used as the template for polymerase
chain reaction (PCR).
One aliquot ofthe ten-fold dilute cDNA solution was used for PCR
in 20 ,ul. Oligonucleotides corresponding to the sense strand of
human MK cDNA (5'-ATGCAGCACCGAGGCTTCCT-3': 1-20,
Tsutsui et al, 1991), the antisense strand of MK cDNA (5'-AT-
CCAGGCTTGGCGTCTAGT-3': 655-638, Tsutsui et al, 1991), the
sense strand of human glyceraldehyde 3-phosphate dehydrogenese
(GAPDH) cDNA (5'-TCCCATCACCATCTTCCA-3': 276-293,
Arcari et al, 1984) and in the antisense strand ofGAPDH cDNA (5'-
CATCACGCCACAGTTTCC-3': Arcari et al, 1984) were synthe-
sized and used as primers for PCR. The PCR conditions were as
follows: 35 cycles ofdenaturation (95°C, I min); reanealing (58°C,
2 min) and extension (72°C, 2 min). PCRproducts were analysedby
agarose gel electrophoresis with ethidium bromide staining.
RESULTS
MK expression in primary tumours
We investigated 46 cases of gastrointestinal cancer by RT-PCR to
detect the truncated form of MK. Clinicopathological features of
these tumours were described previously (Aridome et al, 1995).
Among 46 samples obtained from primary tumours, 45 yielded the
full-size MK product corresponding to the PCR band of 450 bp
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Figure 3 MK expression in lymph node metastasis. NC indicates negative control, the intraperitoneal lymph node obtained from a patient with abdominal
aortic aneurysm. Figures indicate case numbers (cf. Table 1). All the lymph node metastasis were found to express both full-size and truncated MK mRNA
(Table 1). Full-size MK PCR product was not detected in only one
sample from the primary lesion of hepatocellular carcinoma. On
the other hand, a 280-bp band due to the truncated MK was
expressed in 31 (67C/c) of 46 cases (Table 1). This small type of
MK was expressed in two (100%) of two oesophageal carcinomas,
12 (75%) of 16 gastric carcinomas, seven (56%) of 13 colorectal
carcinomas, five (56%c) of nine hepatocellular carcinomas, four
(80%) offive pancreatic cancers and one (100%) of one ampullary
duodenal carcinoma.
In gastric carcinoma, truncated MK was not expressed in
tumours at stage I according to the TNM classification, but was
detected in those at stage II or greater. Interestingly, 11 (92%) of
12 gastric cancer patients in whom truncated MK was expressed in
primary lesions had nodal metastases.
Representative results of RT-PCR analysis are shown in Figure
1. Cases 1 and 2 were gastric carcinomas with metastatic involve-
ment but case 8 was early-stage gastric cancer without metastasis.
Truncated MK was detected in advanced (cases 1 and 2) but not in
early cancer (case 8). In primary lesions of colon carcinomas with
familial polyposis (cases 18 and 21), one of two cases was positive
for the truncated form. In pancreatic carcinoma with hepatic
metastasis (case 40) and oesophageal carcinoma with nodal metas-
tasis (case 44), truncated MK was also detected.
MK expression in adjacent non-cancerous tissues
We investigated 46 samples of adjacent non-cancerous tissue by
RT-PCR. Truncated MK was not expressed in any of these
gastrointestinal tissues.
Full-size MK was detected in all the non-cancerous tissues of
the stomach, oesophagus and large bowel. In two samples of five
non-cancerous tissues of the pancreas full-size MK was also
expressed.
Representative results of MK expression in non-cancerous
tisxue are shown in Figure 2. Truncated MK was not detected in
the precancerous polypioid mucosa from familial polyposis in
cases 18 and 21. In two cases of cirrhotic liver, the full-size MK
was detected by RT-PCR.
When we examined the non-cancerous tissues of the liver by
RT-PCR, full-size MK was detected in four of ten samples. MK
was detectable in three of four cases with cirrhotic tissues of the
liver (cases 30, 31, 34 and 35) and in one of two cases with chronic
hepatitis. On the other hand, MK was not detected in histologically
normal liver tissue.
2 40 47
. Full-size
MK
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Figure 4 MK expression in hepatic metastasis. Lane 2, gastric carcinoma;
lane 40, pancreatic carcinoma; lane 47, extrahepatic bile duct carcinoma.
Only full-size MK was detected in the hepatic metastatic sites
MK expression in metastatic sites
It is noteworthy that truncated MK was expressed in all of 14
metastatic lymph nodes from ten patients but not in one para-aortic
lymph node obtained from a non-tumour-bearing patient with
abdominal aortic aneurysm (Figure 3). In all of ten patients with
nodal involvement, both primary tumour and metastatic lymph
node expressed truncated MK. On the other hand, in three samples
from hepatic metastatic sites (cases 2, 40 and 47), full-size MK
was expressed but the truncated type was not (Figure 4). In case 2
(gastric cancer) and case 40 (pancreatic cancer), primary tumours
were available for analysis and were revealed to have both the
truncated and full-size MK.
DISCUSSION
Truncated MK was detected in 30 of 46 primary cancers of the
gastrointestinal organs examined but not in the adjacent non-
cancerous tissue. Thus, the present results established the cancer-
specific nature of the truncated MK at least in the gastrointestinal
organs. Previously, truncated MK was detected in two ofthree cases
of gastric carcinoma, one of three cases of pancreatic carcinoma,
one of two cases ofWilms' tumour and 5 of25 cases ofcolon carci-
noma and 6 of26 cases ofbreast carcinoma, but not in the following
non-cancerous tissues: pancreatic tissue in three cases, kidney tissue
in one case, colon tissue in one case or breast tissue in eight cases
(Kaname et al, 1996; Miyashiro et al, 1996, 1997). These results are
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inconclusive, except in colon and breast carcinoma. Furthermore,
the present study also revealed the existence of truncated MK in
hepatocarcinoma and oesophageal carcinoma.
Two cases of familial polyposis with colon carcinoma (cases 18
and 21, Table 1) were of special interest from the view point of
tumour-specific expression of truncated MK: in both cases, trun-
cated MK was detected in the cancerous region, but not in the
polypoid region. Truncated MK was also expressed in low-grade
malignant cancer of the pancreas (case 43, Table 1). Thus, cancer
status ofthe tumour region appears to determine whether truncated
MK is expressed.
The full-size MK was detected by RT-PCR in most cancerous
and non-cancerous regions. This conclusion is consistent with data
reported in previous publications (Aridome et al, 1995), although
quantitative Northern blotting analysis revealed stronger MK
expression in more of the cancerous tissues than corresponding
non-cancerous tissue (Aridome et al, 1995). Because of the higher
sensitivity of RT-PCR, the number of MK-positive cases in the
present study was slightly increased in both cancerous and non-
cancerous specimens compared with the previous report (Aridome
et al, 1995) in which Northern blotting analysis was employed.
However, it should be noted that MK was not detected in normal
liver even using RT-PCR.
The most interesting finding of the present study was that all of
14 lymph node metastases from ten cancer patients expressed the
truncated MK mRNA. The finding suggests the possible impor-
tance of the truncated MK in lymph node metastasis. In addition,
truncated MK may have diagnostic value. Further studies in this
subject are urgently required.
All ofthree cases ofmetastatic tumours in the liverdid not express
truncated MK. Furthermore, the expression of full-size MK mRNA
was decreased in the hepatic metastatic lesions as determined by
quantitative Northern blotting analysis (data are not shown).
Therefore, it is possible that both truncated and full-size MK are
correlated with nodal metastasis rather than hepatic metastasis.
There have been reports that molecular biological examination
is useful for detecting micrometastasis in cancer patients (Hayashi
et al, 1994; Hayashi et al, 1995; Inoue et al, 1995; Mori et al,
1995). Inoue et al ( 1995) found hepatic micrometastasis in pancre-
atic adenocarcinoma patients using a two-stage PCR
reaction/restriction fragment length polymorphism analysis, which
detected the K-ras mutation. Concerning lymph node metastases
of gastrointestinal carcinomas, a mutant-allele-specific amplifica-
tion method was used to detect tumour cells with K-ras or p53
mutation (Hayashi et al, 1994, 1995). Cancer cells in lymph nodes
were also detected by carcinoembryonic antigen-specific nested
reverse transcriptase polymerase chain reaction (Mori et al 1995).
Because of the cancer-specific expression of truncated MK, MK-
specific RT-PCR should be useful for the detection of metastatic
cancer cells in lymph nodes. MK-specific RT-PCR would be espe-
cially helpful in accurate diagnosis of borderline lesions between
malignant tumours and benign diseases.
A remaining question is that of the relevance of the truncated
transcript to cancer biology. Staining of cancer specimens with
anti-MK antibody, which will recognize both the intact and the
truncated MK protein, revealed that the cancer cells and not the
infiltrating inflammatory cells produce the MK antigen (Aridome
et al, 1995). The truncated MK retains the C-terminally located
domain, which is responsible for at least two MK activities, neurite
outgrowth (Muramatsu et al, 1994) and enhancement of plas-
minogen activator activity (Kojima et al., l995c). Thus, it is not
likely that the truncated MK exerts some unusual activity.
However, the truncated MK is more susceptible to protease
(Matsuda et al., 1996), and a proteolytically produced fragment
may either interfere with normal MK function or may have new
function relevant to tumour invasion. Several experiments are
possible to test the hypotheses.
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